Skip to main content

JAK/TYK2

      Getting more data on using deucravacitinib for PsO/PsA manifestations
      Impressive effect on scalp psoriasis (which often
      1 month ago
      Getting more data on using deucravacitinib for PsO/PsA manifestations Impressive effect on scalp psoriasis (which often means a lot to patients) Given how safe it is, it's increasingly tempting to use more of it in mild-mod PsA #ACR24 PSORIATYK SCALP trial ABST1137 @RheumNow https://t.co/vxS3RSlIN0
      #1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT

      ➡️n=290, randomised to PBO, 5/15/30mg gps

      💥30mg g
      #1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT ➡️n=290, randomised to PBO, 5/15/30mg gps 💥30mg group 📉 Rapid skin improvement @ Wk 2 ➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004) 🛟Well tolerated ⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains #ACR @RheumNow https://t.co/5GusMlVkQ4
      Exciting early data for new highly selective TYK2i zasocitinib

      Improved PASI skin scores (though not as much as IL23i..
      1 month ago
      Exciting early data for new highly selective TYK2i zasocitinib Improved PASI skin scores (though not as much as IL23i...) Funky skin-related adverse events at higher doses, not sure what to make of that? #ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh
      It’s been eight years, and here we are again. The ACR annual meeting was last in Washington DC in 2016, and there’s probably a lot about ACR 2024 in DC that seems familiar. Maybe for some, it’s the…
      Day 1 Recap at ACR24
      This year at #ACR24, emulation trials are being presented.Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized…
      ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session…
      ×